LNA-mediated microRNA silencing in non-human primates

By Joacim Elmén, M. Lindow, Sylvia Schütz, M. Lawrence, A. Petri, S. Obad, M. Lindholm, Maj Hedtjärn, H. Hansen, U. Berger and 5 more. Nature, 2008

1,646 citations recorded by the source corpus.

Subfields: Cancer Research, Molecular Biology

View Paper: https://www.semanticscholar.org/paper/5cdf6bb2f19727c251cc996c3aac107f88773d6b

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cancer Research

In Molecular Biology

Citations in the corpus

MicroRNA: Biogenesis, Function and Role in Cancer (2010, background): “A variety of chemical modifications can be made to increase the stability and potency of antagomirs, including 2’-O-methyl modified ribose sugars [14], 2’-O-methoxyethyl-modified ribose sugars [13] and addition of an extra 2’-O, 4’-C methylene bridge in the ribose sugar [362].”
MicroRNAs in Common Human Diseases (2012, background): “This miRNA drug demonstrated impressive repression efficacy on miR-122 in mice [105] and in African green monkeys [106], as well as anti-viral efficacy in chimpanzees chronically infected by HCV [74].”
Progress in corneal wound healing (2015, background): “A uthor M anuscript A uthor M anuscript A uthor M anuscript A uthor M anuscript cholesterol by targeting simultaneously a number of cholesterol biosynthesis genes in mice and non-human primates (Elmen et al., 2008a, 2008b; Krützfeldt et al., 2005).”
Targeting MicroRNAs in Cancer: Rationale, Strategies and Challenges (2010, neutral): “The simple systemic delivery of an unconjugated LNA anti-miR-122 (SPC3649, developed by Santaris Pharma) has also been shown to effectively antagonize liver-expressed miR-122 in non-human primate”
MicroRNA Functions in Stress Responses (2010, neutral): “Anantagomir againstmiR-122hasbeendemonstrated in animals to lower hepatitis C virus replication levels and cholesterol levels (Elmen et al., 2008; Krutzfeldt et al., 2005; Lanford et al., 2010).”
MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics. A comprehensive review (2012, neutral): “An efﬁcacy study conducted by Elmen et al on non-human primates (Elmen et al, 2008a), showed a dose-dependent sequestration of mature miR-122 and a long lasting decrease of total plasma cholesterol.”